We are live on ! Find out more
NVIV

InVivo Therapeutics Holdings Corp
NVIV

Delisted

NVIV was delisted on the 12th of February, 2024.

Back to rankings

21 hedge funds and large institutions have $2.4M invested in InVivo Therapeutics Holdings Corp in 2021 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,000% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 1

958% more capital invested

Capital invested by funds: $227K → $2.4M (+$2.17M)

500% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 1

91% more funds holding

Funds holding: 11 → 21 (+10)

Holders
21
Holders Change
+10
Holders Change %
+90.91%
% of All Funds
0.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
6
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$1.3M
2
Renaissance Technologies
Renaissance Technologies
New York
+$364K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$346K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$171K
5
VF
Virtu Financial
New York
+$167K

Top Sellers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
-$54.6K
2
Two Sigma Advisers
Two Sigma Advisers
New York
-$48K

NVIV Hedge Fund Activity: Q1 2021 in Review

21 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in InVivo Therapeutics Holdings Corp (NVIV) for Q1 2021, worth a combined $2.4M — up 958% from $227K a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new NVIV positions and 1 closed out — a net gain of 10 holders — while 6 added to existing stakes and 1 trimmed.

The largest buyer was BlackRock, adding an estimated $1.3M. The largest seller was Tower Research Capital (TRC), cutting an estimated $54.6K.

  • 21 institutional investors held InVivo Therapeutics Holdings Corp (NVIV) as of Q1 2021, up from 11 in Q4 2020.
  • Funds reported $2.4M of InVivo Therapeutics Holdings Corp stock for Q1 2021, up 958% quarter-over-quarter.
  • 11 funds opened new InVivo Therapeutics Holdings Corp positions in Q1 2021 and 1 closed out, a net change of +10 holders.
  • The largest InVivo Therapeutics Holdings Corp buyer in Q1 2021 was BlackRock, an estimated $1.3M added.
  • The largest InVivo Therapeutics Holdings Corp seller in Q1 2021 was Tower Research Capital (TRC), an estimated $54.6K sold.

Based on aggregated 13F filings for Q1 2021.